RxDoctor Payments Data

Karli Brubaker, PA

Physician Assistant · Flint, MINPI 1558873166

Payments from drug & device makers

$2,388in general payments, 2019–2025

Across 122 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$398
  • Novo Nordisk$319
  • GSK$288
  • AbbVie$203
  • Otsuka America Pharmaceutical, Inc.$188
  • Lilly USA, LLC$160
  • plus $833 from 19 others

What the payments were for

  • Food & beverage$2,388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,388 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$33,786
Medicare patients
160
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$88,003
MounjaroTirzepatide52$52,746
TrulicityDulaglutide26$40,338
FarxigaDapagliflozin Propanediol41$33,120
EliquisApixaban32$31,561
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$26,743
JardianceEmpagliflozin16$23,488
JanuviaSitagliptin Phosphate16$16,135
XareltoRivaroxaban12$12,403
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,460
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen405$5,584
Spiriva HandihalerTiotropium Bromide11$5,391
Ventolin HfaAlbuterol Sulfate35$2,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,334
Pregabalin43$1,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$160$93,08478 claims
Novo NordiskOzempic$319$88,00360 claims
AstraZenecaFarxiga, Breztri Aerosphere$398$40,58052 claims
GSKTrelegy Ellipta$288$26,74335 claims
Boehringer IngelheimJardiance$31$23,48816 claims
Johnson & JohnsonXarelto$24$12,40312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →